Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOLINE-2: Donepezil vs Non-drug Approach in Newly Diagnosed Alzheimer's Disease
NCT04661280Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of donepezil in Alzheimer's disease (AD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Mini-Mental State Examination at 26 weeks. Started Feb 2022; status: recruiting.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04661280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661280.